Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma

Cancer

Volumn 101, Issue 7, 2004, Pages 1545-1551

  Nanus, David M ^a   Garino, Alexandria ^b   Milowsky, Matthew I ^a   Larkin, Maureen ^b   Dutcher, Janice P ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Chemotherapy; Doxorubicin; Gemcitabine; Kidney carcinoma; Sarcomatoid renal carcinoma

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; INTERFERON; INTERLEUKIN 2; THALIDOMIDE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DRUG RESPONSE; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LUNG TOXICITY; MALE; NAUSEA; PRIORITY JOURNAL; RASH; SARCOMATOID KIDNEY CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; THROMBOPHLEBITIS; VAGINITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, RENAL CELL; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SARCOMA;

EID: 4844231761     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20541     Document Type: Article

References (31)

1. Milowsky MI, Nanus DM. Chemotherapeutic strategies for renal cell carcinoma. Urol Clin North Am. 2003;30:601-609.
2. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am. 1993;20:303-321.
3. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol. 2000;27:177-186.
4. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163:408-417.
5. Rini BI, Vogelzang NJ, Dumas MC, Wade JL III, Taber DA, Stadler WM. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol. 2000;18:2419-2426.
6. Bleumer I, Oosterwijk E, De Mulder P, Mulders PF. Immunotherapy for renal cell carcinoma. Eur Urol. 2003;44:65-75.
7. Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol. 2001;25:275-284.
8. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612-624.
9. Mian BM, Bhadkamkar N, Slaton JW, et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol. 2002;167:65-70.
10. Culine S, Bekradda M, Terrier-Lacombe MJ, Droz JP. Treatment of sarcomatoid renal cell carcinoma: is there a role for chemotherapy? Eur Urol. 1995;27:138-141.
11. Bangalore N, Bhargava P, Hawkins MJ, et al. Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature. Ann Oncol. 2001;12:271-274.
12. Amato RJ. Therapy for patients with uncommon histologic varieties of renal cell carcinoma. In: Bukowski RM, Novick AC, editors. Renal cell carcinoma: molecular biology, immunology, and clinical management. Totowa, NJ: Humana Press, 2000:397-405.
13. Escudier B, Droz JP, Rolland F, et al. Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. J Urol. 2002;168: 959-961.
14. Milowsky MI, Rosmarin A, Tickoo SK, Papanicolaou N, Nanus DM. Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer. 2002;94:111-116.
15. Dodd PM, McCaffrey JA, Hilton S, et al. Phase I evaluation of sequential doxorubicin, gemcitabine then ifosfamide, paclitaxel, cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol. 2000;18:840-846.
16. Neri B, Doni L, Gemelli MT, et al. Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer. J Urol. 2002;168:956-958.
17. Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol. 1999;17:523-528.
18. Grabowski M, Huzarski T, Lubinski J, Sikorski A. Survival in patients with rare subtypes of renal cell carcinoma. BJU Int. 2002;89:599-600.
19. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;98:2566-2575.
20. Stadler WM, Huo D, George C, et al. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol. 2003;170:1141-1145.
21. Sella A, Logothetis CJ, Ro JY, Swanson DA, Samuels ML. Sarcomatoid renal cell carcinoma. A treatable entity. Cancer. 1987;60:1313-1318.
22. Bangalore N, Bhargava P, Hawkins MJ, Bhargava P. Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature. Ann Oncol. 2001;12:271-274.
23. Hoshi S, Satoh M, Ohyama C, et al. Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma. Int J Clin Oncol. 2003;8:113-117.
24. Neri B, Cini G, Doni L, et al. Weekly gemcitabine plus epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study. Br J Cancer. 2002; 87:497-501.
25. Neri B, Doni L, Fulignati C, et al. Gemcitabine plus epidoxorubicin as first-line chemotherapy for bladder cancer in advanced or metastatic stage: a phase II [sic]. Anticancer Res. 2002;22:2981-2984.
26. Jassem J. Gemcitabine and anthracyclines in breast cancer. Semin Oncol. 2003;30:11-14.
27. Mertens WC, Eisenhauer EA, Moore M, et al. Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 1993;4:331-332.
28. de Mulder PH, Weissbach L, Jakse G, Osieka R, Blatter J. Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol. 1996;37:491-495.
29. George CM, Vogelzang NJ, Rini BI, Geoffroy FJ, Kollipara P, Stadler WM. A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. Ann Oncol. 2002;13:116-120.
30. Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM. A high rate of venous thromboembolism in a multiinstitutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer. 2002;95:1629-1636.
31. Ryan CW, Vogelzang NJ, Stadler WM. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-α in patients with metastatic renal cell carcinoma. Cancer. 2002;94:2602-2609.